Baseline characteristics: per-protocol population
Characteristics . | n = 43 . |
|---|---|
| Age, mean y ± SD (range) | 47.9 ± 14.8 (13-73) |
| Less than 18 y, no. patients | 2 |
| 18 y or older, no. patients | 41 |
| Sex, no. patients | |
| Male | 32 |
| Female | 11 |
| Performance status (ECOG), no. patients | |
| 0 | 9 |
| 1 | 20 |
| 2 | 10 |
| 3 | 4 |
| Median time from transplantation to PTLD diagnosis, m (range) | 51.8 (2.9-186) |
| 1 y or less, no. patients | 14 |
| More than 1 y, no. patients | 29 |
| Ann Arbor lymphoma staging, no. patients | |
| I-II | 11 |
| III-IV | 32 |
| No. involved sites, no. patients | |
| 1 | 14 |
| 2-3 | 12 |
| 4-5 | 12 |
| More than 5 | 5 |
| Lactate dehydrogenase levels, no. patients | |
| Normal | 15 |
| Above normal | 28 |
| Cell EBV viral load, no. patients | |
| Less than 600 copies/μg | 21 |
| 600 copies/μg or more | 18 |
| Missing | 4 |
| Histologic findings, no. patients | |
| Polymorphic | 4 |
| Monomorphic | 28 |
| Unclassified | 5 |
| Not reviewed | 6 |
Characteristics . | n = 43 . |
|---|---|
| Age, mean y ± SD (range) | 47.9 ± 14.8 (13-73) |
| Less than 18 y, no. patients | 2 |
| 18 y or older, no. patients | 41 |
| Sex, no. patients | |
| Male | 32 |
| Female | 11 |
| Performance status (ECOG), no. patients | |
| 0 | 9 |
| 1 | 20 |
| 2 | 10 |
| 3 | 4 |
| Median time from transplantation to PTLD diagnosis, m (range) | 51.8 (2.9-186) |
| 1 y or less, no. patients | 14 |
| More than 1 y, no. patients | 29 |
| Ann Arbor lymphoma staging, no. patients | |
| I-II | 11 |
| III-IV | 32 |
| No. involved sites, no. patients | |
| 1 | 14 |
| 2-3 | 12 |
| 4-5 | 12 |
| More than 5 | 5 |
| Lactate dehydrogenase levels, no. patients | |
| Normal | 15 |
| Above normal | 28 |
| Cell EBV viral load, no. patients | |
| Less than 600 copies/μg | 21 |
| 600 copies/μg or more | 18 |
| Missing | 4 |
| Histologic findings, no. patients | |
| Polymorphic | 4 |
| Monomorphic | 28 |
| Unclassified | 5 |
| Not reviewed | 6 |